Meditech's contribution to cancer fight
17 May, 2002 by Daniella GoldbergMeditech Research has completed Phase I clinical trials of its anti-cancer therapy HyDox, indicating the treatment is safe for patients with breast cancer, renal carcinoma, sarcoma and prostate cancer.
Ambri hopes its tech can prevent endoscopy injury
16 May, 2002 by Daniella GoldbergAmbri is looking to expand the potential applications of its critical care diagnostic system, SensiDx System, enabling surgeons to rapidly detect bowel damage that can occur during an operation.
Premier Bionics' IPO set to make target
16 May, 2002 by Tanya HollisDevice and diagnostics investment company Premier Bionics is on track to close its initial public offering tomorrow (May 17) oversubscribed.
ResMed buys motor company
16 May, 2002 by Daniella GoldbergStrengthening its foothold in the US, ResMed has acquired the Californian manufacturing company, Servo Magnetics Inc (SMI) for about $US32 million ($58.38 million).
Victorian feature: Infrastructure key to biotech success
16 May, 2002 by Tanya Hollis and Melissa TrudingerThe need to build Victoria's biotechnology infrastructure base has been recognised through the establishment of the Biotechnology Platform Technology Working Party.
Victorian feature: Smaller players face big issues
16 May, 2002 by Tanya Hollis and Melissa TrudingerWhile Victorian companies who have been around the block a few times reckon the latest batch of biotech newcomers have got it relatively easy, the feeling out there is quite different.
Clone International looks to NZ for bulls
16 May, 2002 by Melissa TrudingerClone International has crossed the Tasman in its search for elite dairy bulls. A joint venture agreement has been signed with NZ artificial breeding company Ambreed New Zealand.
Peptech wins three more US patents
15 May, 2002 by Daniella GoldbergSydney-based company Peptech has been issued three divisional applications by the US Patent and Trademarks Office in respect of its TNF antibody patent, bringing the antibody's patent tally to four.
We should test for BSE, say lobbyists
14 May, 2002 by Tanya HollisAustralia was guilty of resting dangerously on its laurels in relation to testing for mad cow disease, according to a new education foundation.
AustCancer identifies breast cancer treatment compounds
14 May, 2002 by Daniella GoldbergNovel compounds for breast cancer treatment have been identified by Perth-based company Australian Cancer Technology (AustCancer) through backing by UK-based drug discovery company, BioFocus.
New national centre for plant genomics
13 May, 2002 by Daniella GoldbergThe University of Adelaide has won the bid to host the new $32 million National Centre for Plant Functional Genomics.
Chemeq on the fundraising trail
13 May, 2002 by Tanya HollisPerth-based pharmaceutical company Chemeq has raised almost $5 million from institutional investors and hopes to reap a further $5 million from ordinary shareholders by the end of the month.
Novogen subsidiary to list in London
10 May, 2002 by Daniella GoldbergNovogen's US subsidiary, Edward Marshall, plans to list on the Alternative Investment Market of the London Stock Exchange at the end of the month.
Prima reports 100 per cent success in cancer trial
10 May, 2002 by Tanya HollisA treatment to encourage the immune systems of cancer patients to attack the disease has proven 100 per cent effective in early stage results.
Cryosite makes ASX debut
09 May, 2002 by Daniella GoldbergAustralia's first for-profit tissue banking service company, Cryosite, listed on the ASX today (May 9).
